Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

Gomollón F(2017)3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management J Crohns Colitis. 11 3-25

Dignass A(2009)The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases J Pharmacol Exp Ther 330 864-875

Annese V(2016)An overview of the mechanism of action of the monoclonal antibody vedolizumab J Crohns Colitis. 10 1437-1444

Soler D(2013)Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 699-710

Chapman T(2013)Vedolizumab as induction and maintenance therapy for Crohn’s disease N Engl J Med 369 711-721

Yang LL(2014)Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed Gastroenterology 147 618-627

Wyant T(2012)Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population Clin Gastroenterol Hepatol 10 1002-1007

Fedyk E(2016)Real-world evidence—what is it and what can it tell us? N Engl J Med 375 2293-2297

Abhyankar B(2015)Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort Inflamm Bowel Dis 21 2879-2885

Feagan BG(2005)Systematic reviews and meta-analysis Singapore Med J 46 270-273

Gomollón F(2017)3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management J Crohns Colitis. 11 3-25

Dignass A(2009)The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases J Pharmacol Exp Ther 330 864-875

Annese V(2016)An overview of the mechanism of action of the monoclonal antibody vedolizumab J Crohns Colitis. 10 1437-1444

Soler D(2013)Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 699-710

Chapman T(2013)Vedolizumab as induction and maintenance therapy for Crohn’s disease N Engl J Med 369 711-721

Yang LL(2014)Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed Gastroenterology 147 618-627

Wyant T(2012)Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population Clin Gastroenterol Hepatol 10 1002-1007

Fedyk E(2016)Real-world evidence—what is it and what can it tell us? N Engl J Med 375 2293-2297

Abhyankar B(2015)Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort Inflamm Bowel Dis 21 2879-2885

Feagan BG(2005)Systematic reviews and meta-analysis Singapore Med J 46 270-273